<DOC>
	<DOCNO>NCT00002487</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Dipyridamole may increase effectiveness methotrexate kill tumor cell . PURPOSE : Phase II trial study effectiveness combine methotrexate dipyridamole treat patient advanced ovarian cancer recurrent refractory cisplatin-based chemotherapy .</brief_summary>
	<brief_title>Methotrexate Plus Dipyridamole Treating Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine clinical complete partial response rate , pathological complete response rate , disease-free survival , duration response produce intraperitoneal dipyridamole/methotrexate ( DP/MTX ) administer 7-day continuous infusion patient advance ovarian carcinoma recurrent follow refractory cisplatin-based chemotherapy . II . Determine peritoneal systemic toxicity DP/MTX . OUTLINE : Nonrandomized study . Single-Agent Chemotherapy Chemopotentiation . Methotrexate , MTX , NSC-740 ; Dipyridamole , DP , NSC-515776 . PROJECTED ACCRUAL : Up 40 evaluable patient category ( prior intraperitoneal vs. prior intravenous platinum-based chemotherapy ) study . If response see first 20 patient either category , accrual category cease . An accrual rate 15 patients/year anticipate .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , Stage III/IV ovarian carcinoma refractory recurrent within 1 year complete response intraperitoneal intravenous platinumbased chemotherapy Debulking surgery must consider completion prior chemotherapy ( failure debulk exclude ) Clinical radiographic evidence advance , predominantly peritoneal disease physical exam , CT MRI scan , exploratory laparotomy , peritoneal cytology elevate CA125 ( 35 unit Ottawa Civic General Hospitals ) require Disease limit peritoneal cavity require , peritoneal disease constitute main lifethreatening symptomproducing component Good distribution contrast medium throughout peritoneal cavity CT abdomen pelvis require Measurable , evaluable , unevaluable disease size acceptable PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : More 2 month Hematopoietic : WBC least 3,000 Platelets least 100,000 Hepatic : Bilirubin le 3 X ULN SGOT le 3 x ULN Renal : Creatinine le 1.7 mg/dl ( 150 micromoles/liter ) BUN le 42 mg/dl ( 15 mmoles/liter ) Other : No requirement DP MTX medication know interact DP , ( i.e. , antiplatelet anticoagulant drug ) MTX ( i.e. , chemotherapeutic agent ) No second malignancy basal cell carcinoma skin PRIOR CONCURRENT THERAPY : Recovery toxicity prior therapy require Biologic therapy : Not specify Chemotherapy : Prior platinumbased chemotherapy require No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior abdominopelvic pelvic radiotherapy No concurrent peritoneal radiotherapy Surgery : See Disease Characteristics Other : No concurrent antiplatelet vasodilatory agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>